Evidence map›Paper›PMID 38290482›Full record

ArticleOncology2024

Efficacy of Nanoparticle Albumin-Bound Paclitaxel (nab-PTX) Monotherapy Can Be Improved after Treatment with Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer: Long-Term Follow-Up and Updated Analysis of Two Previous Prospective Clinical Studies.

Koki Nakashima, Yukihiro Umeda, Yoshiki Demura, Tomoaki Sonoda, Toshihiko Tada, Makiko Yamaguchi, Masaki Anzai, Maiko Kadowaki, Masahiro Oi, Chisato Honjo and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Koki NakashimaThird Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Yukihiro UmedaThird Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Yoshiki DemuraDepartment of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Fukui, Japan.
Tomoaki SonodaThird Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Toshihiko TadaDepartment of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Fukui, Japan.
Makiko YamaguchiThird Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Masaki AnzaiThird Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Maiko KadowakiThird Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Masahiro OiDepartment of Respiratory Medicine, Japanese Red Cross Fukui Hospital, Fukui, Japan.
Chisato HonjoThird Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Miho MitsuiThird Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Yuko WasedaThird Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Tamotsu IshizukaThird Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRecent studies have suggested enhanced therapeutic effects of subsequent chemotherapy after immune checkpoint inhibitor (ICI) treatment, highlighting the importance of subsequent treatment selection. Nanoparticle albumin-bound paclitaxel (nab-PTX) is commonly used in subsequent chemotherapies; however, its efficacy as a subsequent treatment after ICI treatment has not been reported.

methodsWe retrospectively evaluated the efficacy and safety of nab-PTX using two prospective studies that we previously reported. The first study evaluated the efficacy and safety of nab-PTX as a second-line treatment after the failure of the first-line cytotoxic chemotherapy, excluding ICI (study 1; n = 32), and the other as a subsequent treatment after failure of ICI treatment, regardless of treatment line (study 2; n = 29).

resultsThe objective response rate was significantly higher in study 2 {55.2% (95% confidence interval [CI]: 28.1-79.6)} than in study 1 (28.1% [95% CI: 13.7-46.7]) (p = 0.04). Although the disease control rate was slightly higher in study 2 (86.2% [95% CI: 65.9-97.0]) than in study 1 (71.9% [95% CI: 53.3-86.3]), there was no significant difference (p = 0.2). The median progression-free survival was significantly longer in study 2 than in study 1 (3.9 months [95% CI: 2.0-5.5] in study 1 vs. 5.6 months [95% CI: 3.0-12.8] in study 2; hazard ratio [HR]: 0.46 [95% CI: 0.27-0.81], p = 0.006). The median overall survival was slightly longer in study 2 despite the greater number of patients who received nab-PTX in late treatment line, but there was no significant difference between study 1 and study 2 (10.9 months [95% CI: 5.1-16.8] in study 1 vs. 11.9 months [95% CI: 7.6-24.8] in study 2; HR: 0.77 [95% CI: 0.46-1.31], p = 0.34). Safety profiles did not differ between the patients in studies 1 and 2.

conclusionNab-PTX monotherapy may be an effective subsequent treatment option after ICI treatment.

Indexed as

AlbuminsCarcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsLung NeoplasmsAdultAgedAged, 80 and overAlbumin-Bound PaclitaxelFemaleFollow-Up StudiesHumansMaleMiddle AgedNanoparticlesPaclitaxelProspective Studies130-nm albumin-bound paclitaxelAlbumin-Bound PaclitaxelAlbuminsImmune Checkpoint InhibitorsPaclitaxelImmune checkpoint inhibitorNanoparticle albumin-bound paclitaxelNon-small cell lung cancerSubsequent treatment

Identifiers

PMID38290482
PMCPMC11216350

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.